Effectiveness of group arts therapies (art therapy, dance movement therapy and music therapy) compared to group counselling for diagnostically heterogeneous psychiatric community patients: study protocol for a randomised controlled trial in mental health services (the ERA study).
Art therapy
Arts therapies
Counselling
Dance movement therapy
Economic evaluation
Group
Mental health
Music therapy
Process evaluation
Randomised controlled trial
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
26 Aug 2023
26 Aug 2023
Historique:
received:
22
02
2023
accepted:
08
03
2023
medline:
28
8
2023
pubmed:
26
8
2023
entrez:
25
8
2023
Statut:
epublish
Résumé
Arts therapies are widely but inconsistently provided in community mental health. Whilst they are appealing to patients, evidence for their effectiveness is mixed. Trials to date have been limited to one art-form or diagnosis. Patients may hold strong preferences for or against an art-form whilst group therapies rely on heterogeneity to provide a range of learning experiences. This study will test whether manualised group arts therapies (art therapy, dance movement therapy and music therapy) are effective in reducing psychological distress for diagnostically heterogeneous patients in community mental health compared to active group counselling control. A pragmatic multi-centre 2-arm randomised controlled superiority trial with health economic evaluation and nested process evaluation. Adults aged ≥ 18, living in the community with a primary diagnosis of psychosis, mood, or anxiety disorder will be invited to participate and provide written informed consent. Participants are eligible if they score ≥ 1.65 on the Global Severity Index of the Brief Symptom Inventory. Those eligible will view videos of arts therapies and be asked for their preference. Participants are randomised to either their preferred type of group arts therapy or counselling. Groups will run twice per week in a community venue for 20 weeks. Our primary outcome is symptom distress at the end of intervention. Secondary outcomes include observer-rated symptoms, social situation and quality of life. Data will be collected at baseline, post-intervention and 6 and 12 months post-intervention. Outcome assessors and trial statisticians will be blinded. Analysis will be intention-to-treat. Economic evaluation will assess the cost-effectiveness of group arts therapies. A nested process evaluation will consist of treatment fidelity analysis, exploratory analysis of group process measures and qualitative interviews with participants and therapists. This will be the first trial to account for patient preferences and diagnostic heterogeneity in group arts therapies. As with all group therapies, there are a number of logistical challenges to which we have had to further adapt due to the COVID-19 pandemic. Overall, the study will provide evidence as to whether there is an additive benefit or not to the use of the arts in group therapy in community mental health care. ISRCTN, ISRCTN88805048 . Registered on 12 September 2018.
Sections du résumé
BACKGROUND
BACKGROUND
Arts therapies are widely but inconsistently provided in community mental health. Whilst they are appealing to patients, evidence for their effectiveness is mixed. Trials to date have been limited to one art-form or diagnosis. Patients may hold strong preferences for or against an art-form whilst group therapies rely on heterogeneity to provide a range of learning experiences. This study will test whether manualised group arts therapies (art therapy, dance movement therapy and music therapy) are effective in reducing psychological distress for diagnostically heterogeneous patients in community mental health compared to active group counselling control.
METHODS
METHODS
A pragmatic multi-centre 2-arm randomised controlled superiority trial with health economic evaluation and nested process evaluation. Adults aged ≥ 18, living in the community with a primary diagnosis of psychosis, mood, or anxiety disorder will be invited to participate and provide written informed consent. Participants are eligible if they score ≥ 1.65 on the Global Severity Index of the Brief Symptom Inventory. Those eligible will view videos of arts therapies and be asked for their preference. Participants are randomised to either their preferred type of group arts therapy or counselling. Groups will run twice per week in a community venue for 20 weeks. Our primary outcome is symptom distress at the end of intervention. Secondary outcomes include observer-rated symptoms, social situation and quality of life. Data will be collected at baseline, post-intervention and 6 and 12 months post-intervention. Outcome assessors and trial statisticians will be blinded. Analysis will be intention-to-treat. Economic evaluation will assess the cost-effectiveness of group arts therapies. A nested process evaluation will consist of treatment fidelity analysis, exploratory analysis of group process measures and qualitative interviews with participants and therapists.
DISCUSSION
CONCLUSIONS
This will be the first trial to account for patient preferences and diagnostic heterogeneity in group arts therapies. As with all group therapies, there are a number of logistical challenges to which we have had to further adapt due to the COVID-19 pandemic. Overall, the study will provide evidence as to whether there is an additive benefit or not to the use of the arts in group therapy in community mental health care.
TRIAL REGISTRATION
BACKGROUND
ISRCTN, ISRCTN88805048 . Registered on 12 September 2018.
Identifiants
pubmed: 37626418
doi: 10.1186/s13063-023-07232-0
pii: 10.1186/s13063-023-07232-0
pmc: PMC10464011
doi:
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
557Subventions
Organisme : Health Technology Assessment Programme
ID : 17/29/01
Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
BMJ. 2012 Feb 28;344:e846
pubmed: 22374932
BMJ. 2015 Mar 19;350:h1258
pubmed: 25791983
Int J Soc Psychiatry. 1999 Spring;45(1):7-12
pubmed: 10443245
Acta Psychiatr Scand. 2012 Nov;126(5):307-14
pubmed: 22943677
Cochrane Database Syst Rev. 2017 Nov 16;11:CD004517
pubmed: 29144545
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941
Cochrane Database Syst Rev. 2015 Feb 19;(2):CD009895
pubmed: 25695871
BMC Psychiatry. 2013 Oct 01;13:242
pubmed: 24083824
Br J Psychiatry. 2005 Oct;187:366-71
pubmed: 16199797
Br J Psychiatry. 2018 Jan;212(1):42-49
pubmed: 29433611
Int J Epidemiol. 2006 Oct;35(5):1292-300
pubmed: 16943232
J Affect Disord. 2013 Oct;151(1):85-91
pubmed: 23769289
Acta Psychiatr Scand. 2014 Aug;130(2):144-53
pubmed: 24256453
Br J Psychiatry. 2006 Apr;188:303-4
pubmed: 16582054
Psychol Psychother. 2007 Jun;80(Pt 2):183-91
pubmed: 17535593
Br J Psychiatry. 2011 Aug;199(2):132-9
pubmed: 21474494
Cochrane Database Syst Rev. 2013 Oct 04;(10):CD006868
pubmed: 24092546
BMJ. 2008 Oct 31;337:a1864
pubmed: 18977792
Psychother Psychosom. 2013;82(5):319-31
pubmed: 23942318
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
JAMA Psychiatry. 2020 Mar 1;77(3):294-302
pubmed: 31799994
Acta Psychiatr Scand. 2008 Jul;118(1):57-63
pubmed: 18582348
Psychother Psychosom. 2015;84(4):241-9
pubmed: 26022543
Assessment. 2004 Jun;11(2):177-87
pubmed: 15171466
Acta Psychiatr Scand. 2001 Jun;103(6):465-70
pubmed: 11401662
Psychol Med. 1983 Aug;13(3):595-605
pubmed: 6622612
Clin Psychol Rev. 2009 Apr;29(3):193-207
pubmed: 19269725
Cochrane Database Syst Rev. 2011 Dec 07;(12):CD004025
pubmed: 22161383
BMC Psychiatry. 2016 Jan 15;16:4
pubmed: 26768890
Cochrane Database Syst Rev. 2005 Oct 19;(4):CD003728
pubmed: 16235338
Evid Based Ment Health. 2007 Aug;10(3):69-70
pubmed: 17652554
Br J Psychiatry. 2016 Jul;209(1):54-61
pubmed: 27151073